[go: up one dir, main page]

WO2001074394A8 - Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant - Google Patents

Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant

Info

Publication number
WO2001074394A8
WO2001074394A8 PCT/SE2001/000663 SE0100663W WO0174394A8 WO 2001074394 A8 WO2001074394 A8 WO 2001074394A8 SE 0100663 W SE0100663 W SE 0100663W WO 0174394 A8 WO0174394 A8 WO 0174394A8
Authority
WO
WIPO (PCT)
Prior art keywords
betablocker
cholesterol
lowering agent
new combination
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2001/000663
Other languages
English (en)
Other versions
WO2001074394A1 (fr
Inventor
Goeran Bondjers
Olov Wiklund
John Wikstrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0001188A external-priority patent/SE0001188D0/xx
Priority claimed from SE0002352A external-priority patent/SE0002352D0/xx
Priority to MXPA02009705A priority Critical patent/MXPA02009705A/es
Priority to HU0300332A priority patent/HUP0300332A3/hu
Priority to EEP200200570A priority patent/EE200200570A/xx
Priority to HK03103659.3A priority patent/HK1051325B/en
Priority to AU4298501A priority patent/AU4298501A/xx
Priority to DE60125159T priority patent/DE60125159T2/de
Priority to JP2001572136A priority patent/JP2003528928A/ja
Priority to PL01357813A priority patent/PL357813A1/xx
Priority to EP01916044A priority patent/EP1272219B1/fr
Priority to KR1020027013184A priority patent/KR20020086749A/ko
Priority to CA002403160A priority patent/CA2403160A1/fr
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to SK1410-2002A priority patent/SK14102002A3/sk
Priority to AU2001242985A priority patent/AU2001242985B2/en
Priority to IL15158901A priority patent/IL151589A0/xx
Priority to BR0109753-9A priority patent/BR0109753A/pt
Priority to NZ521351A priority patent/NZ521351A/en
Publication of WO2001074394A1 publication Critical patent/WO2001074394A1/fr
Publication of WO2001074394A8 publication Critical patent/WO2001074394A8/fr
Priority to IS6554A priority patent/IS6554A/is
Priority to NO20024732A priority patent/NO20024732D0/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques comprenant un bétabloquant et un hypocholestérolémiant mélangés à un adjuvant pharmaceutiquement tolérable, un diluant ou un excipient. L'invention concerne également un kit de pièces, un procédé de traitement et d'utilisation de ces formulations pour prévenir ou traiter l'athérosclérose, l'hypercholestérolémie et l'hyperlipoprotéinémie.
PCT/SE2001/000663 2000-04-03 2001-03-27 Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant Ceased WO2001074394A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BR0109753-9A BR0109753A (pt) 2000-04-03 2001-03-27 Combinação farmacêutica, formulação farmacêutica, conjunto de partes, método para tratamento profilático ou terapêutico de um paciente que sofre de, ou é suscetìvel a, aterosclerose, e, usos de uma formulação, de uma combinação, ou de um conjunto de partes
NZ521351A NZ521351A (en) 2000-04-03 2001-03-27 New combination of a betablocker and a HMG-CoA reductase inhibitor which are metaprolol and rosuvastatin and the use in the treatment of atherosclerosis
CA002403160A CA2403160A1 (fr) 2000-04-03 2001-03-27 Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant
EEP200200570A EE200200570A (et) 2000-04-03 2001-03-27 Uus beeta-blokaatori ja kolesterooli alandava aine kombinatsioon
HK03103659.3A HK1051325B (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent
AU4298501A AU4298501A (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent
DE60125159T DE60125159T2 (de) 2000-04-03 2001-03-27 Neue kombination von einem beta-blocker und einem cholesterin-senkenden mittel
JP2001572136A JP2003528928A (ja) 2000-04-03 2001-03-27 β遮断薬およびコレステロール低下薬の新組合せ
SK1410-2002A SK14102002A3 (sk) 2000-04-03 2001-03-27 Farmaceutické kombinácie a formulácie, ktoré obsahujú betablokátor a činidlo, ktoré znižuje hladinu cholesterolu, ich použitie a "kit of parts", ktorý ich obsahuje
HU0300332A HUP0300332A3 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent and pharmaceutical compositions containing them
KR1020027013184A KR20020086749A (ko) 2000-04-03 2001-03-27 베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
MXPA02009705A MXPA02009705A (es) 2000-04-03 2001-03-27 Nueva combinacion de un betabloqueador y un agente de disminucion de colesterol.
EP01916044A EP1272219B1 (fr) 2000-04-03 2001-03-27 Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant
PL01357813A PL357813A1 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent
AU2001242985A AU2001242985B2 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholesterol-lowering agent
IL15158901A IL151589A0 (en) 2000-04-03 2001-03-27 New combination of a betablocker and a cholestrol-lowering agent
IS6554A IS6554A (is) 2000-04-03 2002-09-19 Ný samsetning af betatálma og kólesteróllækkandi miðli
NO20024732A NO20024732D0 (no) 2000-04-03 2002-10-02 Ny kombinasjon av en betablokker og et kolesterolsenkende middel

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0001188A SE0001188D0 (sv) 2000-04-03 2000-04-03 New combination
SE0001188-2 2000-04-03
SE0002352A SE0002352D0 (sv) 2000-06-22 2000-06-22 New combination
SE0002352-3 2000-06-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/220,790 A-371-Of-International US20030060477A1 (en) 2000-04-03 2001-03-27 Combination of a betablocker and a cholesterol-lowering agent
US10/824,170 Continuation US20040192784A1 (en) 2000-04-03 2004-04-14 Combination of a betablocker and a cholesterol-lowering agent

Publications (2)

Publication Number Publication Date
WO2001074394A1 WO2001074394A1 (fr) 2001-10-11
WO2001074394A8 true WO2001074394A8 (fr) 2002-05-23

Family

ID=26655059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/000663 Ceased WO2001074394A1 (fr) 2000-04-03 2001-03-27 Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant

Country Status (24)

Country Link
US (2) US20030060477A1 (fr)
EP (1) EP1272219B1 (fr)
JP (1) JP2003528928A (fr)
KR (1) KR20020086749A (fr)
CN (1) CN1422161A (fr)
AR (1) AR030414A1 (fr)
AT (1) ATE347909T1 (fr)
AU (2) AU2001242985B2 (fr)
BR (1) BR0109753A (fr)
CA (1) CA2403160A1 (fr)
DE (1) DE60125159T2 (fr)
EE (1) EE200200570A (fr)
ES (1) ES2276774T3 (fr)
HU (1) HUP0300332A3 (fr)
IL (1) IL151589A0 (fr)
IS (1) IS6554A (fr)
MX (1) MXPA02009705A (fr)
MY (1) MY136386A (fr)
NO (1) NO20024732D0 (fr)
NZ (1) NZ521351A (fr)
PL (1) PL357813A1 (fr)
RU (1) RU2002123591A (fr)
SK (1) SK14102002A3 (fr)
WO (1) WO2001074394A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ITMI20040145A1 (it) * 2004-01-30 2004-04-30 Acraf L-moprololo lpiu' tartrato
WO2005077331A1 (fr) * 2004-02-11 2005-08-25 Athpharma Limited Compositions chronotherapeutiques et procedes d'utilisation
CN102091068B (zh) * 2004-05-03 2012-09-19 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
CN101022791B (zh) * 2004-06-04 2011-11-16 麦兰实验室公司 含奈必洛尔的组合物
CA2657394A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation contenant un agent du type fibrate et methode de production connexe
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
CN102462844A (zh) * 2010-11-05 2012-05-23 四川滇虹医药开发有限公司 一种替利洛尔的药物组合物及其制备方法
WO2013157833A1 (fr) * 2012-04-18 2013-10-24 서울대학교산학협력단 Composition comprenant un bêta-bloquant comme principe actif pour traiter ou diminuer l'obésité, les maladies métaboliques et l'ostéopénie.
CN103613586B (zh) * 2013-11-01 2016-06-08 北京博爱旺康医药科技有限公司 一种旋光纯s-(-)-阿罗洛尔酸式盐及其制备方法和应用
CN103626750B (zh) * 2013-11-15 2016-02-24 北京博爱旺康医药科技有限公司 一种盐酸阿罗洛尔及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
ATE141049T1 (de) * 1991-03-18 1996-08-15 Sepracor Inc Zubereitung und verfahren enthaltend optisch reines s-metoprolol
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
WO1997038694A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
NZ512532A (en) * 1998-12-23 2003-12-19 G Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
US20040192784A1 (en) 2004-09-30
NO20024732L (no) 2002-10-02
AU4298501A (en) 2001-10-15
WO2001074394A1 (fr) 2001-10-11
BR0109753A (pt) 2003-02-04
EP1272219B1 (fr) 2006-12-13
DE60125159T2 (de) 2007-10-25
EP1272219A1 (fr) 2003-01-08
HK1051325A1 (en) 2003-08-01
IL151589A0 (en) 2003-04-10
HUP0300332A3 (en) 2005-03-29
ATE347909T1 (de) 2007-01-15
NZ521351A (en) 2004-08-27
NO20024732D0 (no) 2002-10-02
US20030060477A1 (en) 2003-03-27
PL357813A1 (en) 2004-07-26
CN1422161A (zh) 2003-06-04
ES2276774T3 (es) 2007-07-01
MXPA02009705A (es) 2004-02-26
KR20020086749A (ko) 2002-11-18
JP2003528928A (ja) 2003-09-30
IS6554A (is) 2002-09-19
DE60125159D1 (de) 2007-01-25
CA2403160A1 (fr) 2001-10-11
SK14102002A3 (sk) 2003-06-03
MY136386A (en) 2008-09-30
EE200200570A (et) 2004-04-15
AR030414A1 (es) 2003-08-20
AU2001242985B2 (en) 2005-02-24
RU2002123591A (ru) 2004-03-20
HUP0300332A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
IL245955A0 (en) Immunogenic preparations for the prevention and treatment of inflammatory bowel disease
WO2001074394A8 (fr) Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant
HK1046527A1 (zh) 金剛烷衍生物
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2001066564A3 (fr) Inhibiteurs de gamma-sécrétase
MXPA03010761A (es) Combinaciones farmaceuticas.
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002232558A1 (en) Compounds, compositions and methods for treatment of parasitic infections
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2001278955A1 (en) Use of alpha-keratose as a blood plasma expander
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
CA2432177A1 (fr) Medicaments pour la prevention et/ou la therapie de l'endometriose
AUPQ866500A0 (en) Therapeutic compounds and methods
AU2811400A (en) Stable formulation containing fumagillin
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof
WO2001097751A3 (fr) Nouvelle formulation
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
AU2001255126A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of glomerulosclerosis and renal failure
AU6106801A (en) Trans-clitoral administration of therapy
WO2001060344A3 (fr) Utilisation de thiamphenicol dans preparation compositions pharmaceutiques utiles dans le traitement des infections par des staphylocoques resistant aux intermediaires de vancomycine multiresistants
AU2003285125A1 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU2001253560A1 (en) Methods of treatment
WO2002094377A3 (fr) Preparation pharmaceutique contenant des sels de potassium et de magnesium physiologiquement acceptables et utilisation de ladite preparation pour la prophylaxie et / ou la therapie de l'allongement de l'espace qt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2001916044

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 151589

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/07107

Country of ref document: ZA

Ref document number: 200207107

Country of ref document: ZA

Ref document number: 10220790

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001242985

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2403160

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 521351

Country of ref document: NZ

Ref document number: IN/PCT/2002/01245/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 14102002

Country of ref document: SK

Ref document number: 018076521

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 572136

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009705

Country of ref document: MX

Ref document number: PV2002-3296

Country of ref document: CZ

Ref document number: 1020027013184

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 02089167

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2002 2002123591

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027013184

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-3296

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001916044

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 521351

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 521351

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001242985

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2001916044

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-3296

Country of ref document: CZ